| Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Co. manufactures products in the U.S., Puerto Rico and in four foreign countries. Co. has products in the following therapeutic classes: oncology; cardiovascular; and immunoscience. Co.'s products include: Opdivo; Eliquis; Orencia; Sprycel; Yervoy; Empliciti; Baraclude; the Reyataz Franchise; the Sustiva Franchise; and the Hepatitis C Franchise. We show 40 historical shares outstanding datapoints in our coverage of BMY's shares outstanding history.|
Understanding the changing numbers of BMY shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like BMY versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching BMY by allowing them to research BMY shares outstanding history
as well as any other stock in our coverage universe.